From Melrose Health's debut in the longevity health space to the recall of Uncle Frog's Mushroom Gummies in Australia, and India's ongoing debate on its nutraceutical regulatory framework, here are the most-read stories on NutraIngredients-Asia in July 2024.
Aussie health food firm Melrose Health is debuting a series of longevity-focused dietary supplements that target the declining health span of Australia’s ageing population.
Industry and nutrition experts in Australia suspect THC was included in a lion’s mane and cordyceps range of Uncle Frog’s Mushroom Gummies, which caused consumers to suffer symptoms including hallucinations and seizures.
There is an ongoing discussion between India’s food and drug regulators, as well as industry, on whether vitamins and minerals above one recommended dietary allowance (RDA) and upper limits should be regulated by the drug regulator instead.
Manufacturers of Foods with Function Claims (FFC) are legally bound to four newly added requirements from September 1 – the latest move in regulating Japan’s functional foods industry since Kobayashi Pharmaceutical’s red yeast rice scandal broke out.
New Zealand-based Ārepa is doubling down on ensuring compliance with regulations regarding health claims and product labelling through submission of a scientific dossier, repackaging, and continuous research.
Australia is aiming to topple the US as China’s number one health supplements exporter – a title which it first held in 2018 – on the back of warming political relations and market-focused NPD.
China’s nutraceutical market is seeing burgeoning interest in fish oil omega-3 and liver health, but bone and joint health remains one of the strongest categories, according to our in-depth analysis with experts in the country.
Amway is focusing its resources on several key categories, including gut health and anti-ageing, based on major trends that it has observed and believes possess immense potential for growth.
A new global omega-3 index (O3I) study shows that populations in Japan, South Korea continue to have a desirable level of O3I amongst Asia-Pacific countries, with improvements seen in New Zealand, while that of China and Australia remain lower than moderate levels.
China approved nearly 600 infant formulas based on the new GuoBiao (GB) or national standards last year.
